BACE1 and Parkinson disease: They found such treatment resulted in decrease of ASMase activities, and potentially attributed to α‐Syn protein accumulation, thus supporting an association between SMPD1, ASMase activity, and PD.[299] Park et al. intracranially injected the CRISPR‐Cas9‐loaded nanocomplex, targeting BACE‐1, into the brain of 5XFAD transgenic mice, an AD disease model.